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In cells cultured from neocortex of newborn rats, phosphoinositide-3-kinases of class
I regulate the DNA synthesis in a subgroup of astroglial cells. We have studied the
location of these cells as well as the kinase isoforms which facilitate the S phase entry.
Using dominant negative (dn) isoforms as well as selective pharmacological inhibitors
we quantified S phase entry by nuclear labeling with bromodeoxyuridine (BrdU). Only
in astroglial cells harvested from the marginal zone (MZ) of the neocortex inhibition
of phosphoinositide-3-kinases reduced the nuclear labeling with BrdU, indicating that
neocortical astroglial cells differ in the regulation of proliferation. The two kinase isoforms
p110α and p110β were essential for S phase entry. p110α diminished the level of the
p27Kip1 which inactivates the complex of cyclin E and CDK2 necessary for entry into
the S phase. p110β phosphorylated and inhibited glycogen synthase kinase-3β which can
prevent S-phase entry. Taken together, both isoforms mediated S phase in a subgroup of
neocortical astroglial cells and acted via distinct pathways.
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INTRODUCTION
Class I phosphoinositide-3-kinases (PI3-kinases) generate
phosphoinositide(3,4,5)P3 [PtdIns(3,4,5)P3] by phosphorylating
phosphoinositide(4,5)P2 (Wymann and Pirola, 1998; Cantley,
2002). The kinases are heterodimers of a regulatory subunit and
a catalytic subunit, such as p110α, p110β, p110γ, or p110δ. Apart
from their functions in cell metabolism, survival and migration,
the PI3-kinases play important roles in the regulation of the cell
cycle in normal and cancer cells (Kuemmerle and Bushman,
1998; Cantley, 2002; Zhao et al., 2003; Wymann and Marone,
2005). During the G0 phase, they can mediate the renewed entry
into the cell cycle. They can also facilitate the progression through
the G1 phase of the cell cycle as well as the G2/M transition
(Garcia et al., 2006; Marques et al., 2008).
Initiated by MAP kinases, the protein complexes cyclin
E/CDK2 and cyclin D/CDK4/6 cause the sustained hyperphos-
phorylation of the retinoblastoma protein and thus initiate
S phase entry and DNA synthesis (Garcia et al., 2006; Cross
et al., 2011). PI3-kinases can facilitate the formation and activ-
ity of cyclin/CDK complexes. In aortic smooth muscle cells and
mouse embryonic fibroblasts, PI3-kinases suppress the activ-
ity of p27Kip1 (Bacqueville et al., 1998; Collado et al., 2000),
which inhibits the cyclin E/cdk2 complex (Chu et al., 2008). In
addition, PI3-kinases phosphorylate glycogen synthase kinase-
3β (GSK-3β) at Ser9. This inactivates the GSK-3β which can
prevent S phase entry (Cross et al., 1995; Diehl et al., 1998;
Liang and Slingerland, 2003; Yang et al., 2006; Mao et al.,
2009).
In a pilot study with cultured rat neocortical astroglial cells, the
PI3-kinase inhibitor wortmannin (Arcaro and Wymann, 1993)
reduced by approximately 40% the number of cells which showed
nuclear uptake of bromodeoxyuridine (BrdU), suggesting that
PI3-kinases regulated S phase entry in a subgroup of glial cells.
In the present study, we investigated which p110 isoforms were
involved in this effect. After identifying the isoforms expressed
in astroglial cells, we inactivated them by expressing dominant
negative (dn) isoforms in the cells or by using pharmacological
inhibitors. Our results show that p110α suppressed the activity of
p27Kip1, whereas p110β phosphorylated GSK-3β. We also stud-
ied the neocortical location of the cells which were regulated by
PI3-kinases. Both PI3-kinase isoforms facilitated S phase entry
only in astroglial cells located in the marginal zone (MZ) of the
neocortex.
MATERIALS AND METHODS
ANTIBODIES, DRUGS, AND PLASMIDS
The following antibodies were used: anti-phospho-Akt (Ser473),
anti-Akt, anti-p27Kip1, anti-phospho-GSK-3β (Ser9), anti-GSK-
3β 27C10 (Cell Signaling, Danvers, MA); anti-GAPDH (Millipore
GmbH, Billerica, MA), anti-BrdU (Roche Diagnostics GmbH,
Mannheim, Germany). Peroxidase-coupled secondary antibod-
ies were bought from Rockland/Biomol GmbH (Hamburg).
The following drugs were used: wortmannin, MG-132 (Sigma-
Aldrich, St. Louis, MO), AS-252424, TGX-221 (Axxora, Lörrach,
Germany); CHIR-99021 (Axon Medchem, Groningen, NL). dn
p110βK805R, wildtype (wt) p110β, and dnp110αK833R were kindly
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provided by Nürnberg (Tübingen, Germany); dnp110αK802R and
wtp110α were gifts of Wyman (University Basel, Switzerland).
Oligonucleotides for PCR analysis were bought from Biomers
(Ulm, Germany).
PRIMARY CULTURES OF DISSOCIATED NEOCORTICAL ASTROGLIAL
CELLS
Brains from newborn rats were dissected to culture cells from
total neocortex. To prepare cultures from the MZ or deep lay-
ers of the neocortex, we used brains from 5 day old (P5) rats.
The areas were dissected from cooled, 1mm thick coronal brain
slices. As described previously (Hildebrand et al., 1997), cells were
dispersed with trypsin (Sigma-Aldrich, München, Germany) and
then suspended in Dulbecco’s Modified Essential Medium sup-
plemented with 10% endotoxin-free fetal bovine serum (FBS;
Biochrom AG, Berlin, Germany). Viable cells were seeded in
uncoated six-well plates (35mm diameter, Greiner Bio-One
GmbH, Frickenhausen, Germany). Seeding density was 2.5 × 106
cells per well. The DMEM incubation medium contained 10%
FBS and was renewed after 4 days. Experiments were performed
with semi-confluent cells after 8–10 days in vitro (DIV). Cultures
of rat hippocampal neurons were prepared as described previ-
ously (Benz et al., 1998).
ORGANOTYPIC CULTURES OF NEOCORTEX
Brain hemispheres were dissected from neonate rat pups (P0–P2)
and cut into 400μm coronal cortical sections with a McIlwain
tissue chopper under sterile conditions. Intact slices were placed
on humidified porous Millipore membranes in 6-well plates
containing 1.2ml of serum-based nutrient medium (25% heat-
inactivated horse serum, 50% MEM, and 25% Hanks’ balanced
salt solution supplemented with glutamax at 2mM final concen-
tration). The medium was changed three times per week.
REVERSE TRANSCRIPTION PCR
The RNA of astrocytes cultured from total neocortex and rat
spleen tissue was isolated with the RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol.
One μg of RNA was transcribed into cDNA with Superscript
II Reverse Transcriptase (Invitrogen, Karlsruhe, Germany). For
PCR amplification the following primers were used: p110α
(forward): 5′-TGCGGCCGCCAGGTAGAGGCCATGGAGAA-3′,
p110α (reverse): 5′-TCCATGGGATCTCATTGTTCTGAAACA-
3′; p110β (forward): 5′-AGCGGCCGC-AAACAGGTTGAAG
CACTCAA-3′, p110β (reverse): 5′-CCCATGGCACCGCGTCC
TCT-CCAAAGG-3′; p110γ (forward): 5′-TGCGGCCGCCTGA
GAAGTATGATGTCAGT-3′, p110γ (reverse): 5′-CCCATGGCA
ATGGTTTCATTGGATAGG-3′; p110δ (forward): 5′-TGCGGC
CGCGTGCTGATGAAGCAGGGGGA-3′, p110δ (reverse):
5′-CCCATGGG-CCTGCCTTCTCGCTGCTGT-3′. The PCR
products were verified by sequence analysis.
CELL LYSIS AND WESTERN BLOT ANALYSIS
Western blot experiments were repeated twice. For total cell
extracts, cells were lysed in 1× SDS sample buffer (62.5mM
Tris-HCl, pH 6.8, 2% w/v SDS, 10% glycerol, 50mM DTT,
0.01% bromophenol blue). Equal amounts of cellular pro-
tein lysate were separated on 12.5% polyacrylamide gels and
transferred to polyvinylidene difluoride membranes. After
treatment with 5% non-fat dry milk for 1 h, membranes
were incubated with respective primary antibodies at 4◦C
overnight and then incubated with an appropriate horseradish
peroxidase-conjugated secondary antibody (Biotrend, Köln,
Germany). Bound antibodies were detected using enhanced
chemiluminescent detection reagent [100mM Tris HCl, pH
8.0, 1mM luminol (Fluka/Sigma, Schnelldorf, Germany),
0.2mM p-coumaric acid, and 3mM H2O2], and visualized
with the imaging system LAS-3000 (Fujifilm, Düsseldorf,
Germany).
NUCLEAR UPTAKE OF BROMODEOXYURIDINE (BrdU)
BrdU is incorporated into the nascent DNA during the S phase
of the cell cycle. Astroglial cells were synchronized by FBS with-
drawal for 24 h. If not stated otherwise, 15 h after re-addition of
FBS (final concentration 10%), BrdU (10μM; Roche Diagnostics
GmbH, Mannheim, Germany) was added to the medium for the
last 60min of the incubation. Cells were fixed with methanol
(−20◦C), washed with PBS for 5min, and then incubated with
2N HCl (10min, 37◦C). After the medium had been neutral-
ized with borate buffer (0.1M, pH 8.5), the cells were washed
and incubated for 3 h with a mouse anti-BrdU antibody (Roche
Diagnostics GmbH, Mannheim, Germany). The immune com-
plex was detected with a Cy3 labeled secondary goat anti-
mouse antibody (Dianova, Hamburg, Germany). To estimate the
total cell number, fixed cells were stained with 4′, 6-diamidine-
2′-phenylindole dihydrochloride (DAPI, Invitrogen, Karlsruhe,
Germany) for 10min.
IMMUNOCYTOCHEMISTRY IN SLICE CULTURES
Slice cultures were fixed with 4% PFA in 0.1M PBS for 2 h. After
several washes with PBS, the Millipore membrane with the cul-
tures was cut off, mounted on a planar agar block and re-sliced
into 50μm sections with a vibratome. Denaturation of DNA was
achieved by immersion of free floating sections in 2N HCl at
37◦C for 30min. After several rinses in PBS, slices were incu-
bated in a blocking PBS solution containing 5% normal goat
serum (Vector Labs.) and permeabilized with 0.1% Triton-100
for 30min. For immunolabeling of proliferating astrocytes a poly-
clonal rabbit anti-GFAP antibody (dilution: 1:500, DAKO) and a
mouse anti-BrDU antibody (dilution: 1:1000, DAKO) were used
in PBS containing 1% NGS at 4◦C overnight. After three washes
with PBS for 5min each, the slices were incubated with sec-
ondary antibodies (Cy3-conjugated goat-anti-rabbit IgG, 1:800,
Jackson Immuno Research; Alexa 488 goat-anti-mouse IgG,
1:400, Invitrogen) for 2 h at room temperature in the dark. The
slices were washed three times in PBS followed by DAPI nuclear
stain (1:50,000 Molecular Probes) for a few seconds. Finally, the
slices were extensively washed in PBS for 1 h, mounted on glass
slides and coverslipped. Slices were digitally photographed (Zeiss
ApoTome).
INFECTION OF ASTROGLIAL CELLS WITH ADENOVIRUS SYSTEMS
CONTAINING RECOMBINANT p110 ISOFORMS
The adenoviral constructs used expressed the respective p110 iso-
form linked to enhanced green fluorescent protein (EGFP). The
non-catalytic p110mutants still bound to regulatory subunits and
Frontiers in Cellular Neuroscience www.frontiersin.org March 2013 | Volume 7 | Article 24 | 2
Müller et al. PI3-kinases and proliferation in astrocytes
thus acted in a dn manner. The following recombinant and wt
subunits of PI3-kinase were used: dnp110βK805R and wtp110β
(Yart et al., 2002), dnp110αK802R and wtp110α (Wymann et al.,
1996) as well as dnp110γK833R (Ma et al., 1998). The graded
expression of dnp110βK805R, wtp110β, and dnp110γK833R was
induced with the adenoviral Tet-On system (BD Adeno-X Tet-
On Expression System 2; Clontech Laboratories, Mountain View,
CA) (Gossen and Bujard, 1992). The respective coding regions
were cloned into the tetracycline-responsive pAdeno-X vector.
The vector was modified by introducing the coding sequence for
EGFP and an internal ribosomal entry site (IRES) into the EcoRI
and XhoI sites. Following propagation in HEK 293 cells, the viral
lysate was purified by filtration (pore size 0.45μm). Use of the
Adeno-X Rapid Titer Kit (Clontech Laboratories) gave infectious
units in the range of 3–7 × 109/ml. All constructs were verified
by sequence analysis. Six to seven days after seeding, neocortical
astroglial cells were infected for 24 h with recombinant aden-
ovirus and Tet-On virus [in a ratio of 1:1; multiplicity of infection
(MOI) ∼10]. To induce expression of EGFP and the protein
of interest, doxycycline (600 nM) was added to the incubation
medium for the subsequent 24 h. After this time, the actual exper-
iments were performed. Cultures were only used, if the infection
rate was ≥ 90%, measured by comparing EGFP positive cells to
DAPI positive cells.
For the expression of dnp110αK802R and wtp110α the pAdeno-
X Expression System 1 (Clontech) was used. The coding regions
were cloned into the shuttle vector pShuttle2, which was mod-
ified by introducing an IRES-EGFP insert. Then each construct
together with the IRES-EGFP insert was cloned into the pAdeno-
X vector. Propagation and purification of the viral particles as well
as determination of the viral titers were performed as described
above. Astroglial cells were infected with recombinant adenovirus
6–7 days after seeding (MOI ∼10) and the actual experiments
were performed 48 h after viral infection. In all experiments, we
obtained an infection rate ≥ 90% measured by comparing EGFP
positive cells to DAPI positive cells.
siRNA TRANSFECTION
Semi-confluent astroglial cells were transfected with 100 nM
siRNA using DharmaFECT1 (Dharmacon, Lafayette, CO)
according to the manufacturer’s protocol. The following siRNA-
oligonucleotides (sense strand) were used: p27Kip1siRNA: GCU
CCG AAU UAA GAA UAA U (Qiagen, Hilden; Germany);
GSK-3β siRNA: CGA UUA CAC GUC UAG UAU A (Qiagen,
Hilden, Germany). A non-silencing RNA consisting of a scram-
bled sequence (AllStars Negative Control siRNA, Qiagen, Hilden,
Germany) was used as a control. Experiments were performed
48 h after siRNA transfection.
DATA COLLECTION AND STATISTICAL EVALUATION
Experiments were repeated at least once. For measurement of
BrdU uptake within one experiment, at least three wells of a six-
well plate were used per group. BrdU as well as DAPI positive cells
were counted in an area of 0.1mm2 with use of a Zeiss Axiophot
microscope to calculate the ratio. Five areas were counted per
well. Within one experiment, the mean value of the BrdU/DAPI
ratios of the controls was used to express all groups as percent of
controls. Results from all experiments were compiled for statisti-
cal evaluation, which was made by Kruskal–Wallis’ test followed
by Mann–Whitney U-test. Shown are Means ± CI (0.95%), (n)
indicates the number of all areas counted.
RESULTS
p110α AND p110β REGULATE NUCLEAR BrdU UPTAKE IN CULTURED
NEOCORTICAL ASTROGLIAL CELLS
After 10 DIV, cultures prepared from whole neocortex of new-
born rats contain mainly astroglial cells of type I (≥96%) as
indicated by the presence of glial fibrillary acidic protein and
the absence of A2B5 antigen (Hildebrand et al., 1997). Such
cultures were used to characterize the expressed PI3-kinase iso-
forms. Using RT-PCR andWestern-blotting we found only p110α
and 110β (Figures 1A,B). In contrast, spleen tissue and cultured
hippocampal neurons additionally expressed p110γ or p110δ.
The role of PI3-kinases in S phase entry was studied in semi-
confluent cultures which were synchronized by FBS withdrawal
for 24 h. Re-addition of FBS increased the number of nuclei
which had taken up BrdU. After 14 h, approximately 14% of
DAPI stained nuclei were BrdU labeled (Figure 1C). This ratio
increased to approximately 30% between 16 and 20 h. It dropped
again to 23% after 24 h (Figure 1C). When wortmannin (100 nM)
was added together with FBS, it reduced the number of BrdU pos-
itive nuclei by 40–60% at all time-points measured (Figure 1C).
Apparently, PI3-kinases facilitated G1/S phase transition in a
subpopulation of the astroglial cells.
Next, we studied the roles of p110α and p110β in nuclear BrdU
uptake. To inhibit p110α, we infected the cells with an aden-
viral construct which caused the expression of dnp110αK802R.
Since p110γ is not expressed in our cultures, we additionally used
the pharmacological agent AS-252424, which inhibits p110α and
p110γ (Condliffe et al., 2005). Compared to the respective con-
trols, expression of dnp110αK802R or application of AS-252424
(5μM) reduced the percentage of BrdU labeled nuclei by 50 and
42%, respectively (Figures 2A,C). In contrast, overexpression of
wtp110α increased it by nearly 120% compared to the EGFP
controls (Figure 2A).
To inhibit p110β, we infected the cells with an adenoviral
construct which caused the expression of dnp110βK805R or used
TGX-221, a pharmacological inhibitor. TGX-221 inhibits p110β
10 times more potently than p110δ (Condliffe et al., 2005), which
is not expressed in our cells. The concentration of TGX-221 used
in these experiments was too low to affect p110α and p110γ
(Condliffe et al., 2005). Expression of wild type p110β did not
change the number of BrdU labeled nuclei compared to EGFP
controls, but dnp110βK805R reduced it by approximately 50%
(Figures 2B, 3A). TGX-221 (200 nM) reduced the number of
BrdU labeled nuclei by 38% (Figure 2C). The combination of
As252424 and TGX-221 reduced the number of BrdU labeled
nuclei stronger than their single application. When combined,
they decreased the nuclear BrdU labeling by 60% as did wortman-
nin (Figure 2C). Dnp110γK833R did not change the number of
BrdU nuclei (Figure 2B). As detailed in Materials and Methods,
we used the ratio of BrdU and DAPI stained nuclei, to quan-
tify the effects of the various treatments on DNA synthesis.
Therefore, it was necessary to study, whether the treatments
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FIGURE 1 | p110α and p110β are expressed in cultured neocortical
astrocytes and facilitate nuclear uptake of BrdU. (A) RT-PCR for
p110α, p110β, p110γ, and p110δ in astroglial cultures (as) and spleen
tissue (sp). Samples containing only water (H2O) were used as
negative controls. (B) Western blot from lysates of cultured astroglial
cells (as) and hippocampal neurons (ne). (C) Time-course of the
nuclear uptake of BrdU after re-addition of FBS. To astroglial cells
FBS-starved for 24 h 10% FBS± wortmannin (100 nM, wo) was added
for the indicated time periods. BrdU was present during the last hour
of incubation with FBS. Means ± CI (0.95) are shown; n ≥ 15;
∗ ∼ p < 0.05 compared to 14 h, ∗∗ ∼ p < 0.05 compared to respective
cultures without wortmannin.
changed the number of DAPI stained nuclei. When expressed
for 24 h, none of the recombinant PI3-kinases the number of
DAPI stained nuclei [means ± CI (0.95) per area]: EGFP con-
trols 64.4 ± 10.7; dnp110αK802R 69 ± 12; wtp110α 60 ± 12.5;
dnp110βK805R 55.5 ± 18; wtp110β 55.3 ± 5.5; dnp110γK833R
71.5 ± 27.9. When present for 16 h, also the pharmacologi-
cal inhibitors did not affect these numbers [means ± CI (0.95)
per area]: control 117 ± 45.3; AS-252424 125 ± 32.3; TGX-221:
118 ± 33.6; wortmannin: 119 ± 54.9. When we applied TGX-221
for 3 days, however, it significantly reduced the number of DAPI
stained nuclei by approximately 40% (Figure 3B), indicating a
decrease in total cell number. This reduction was in agreement
with an inhibitory effect on proliferation.
p110α FACILITATES G1/S PHASE PROGRESSION BY REDUCING
P27KIP1 LEVELS
PI3-kinases diminish the cytosolic and nuclear levels of the CDK-
inhibitor p27Kip1 and thereby maintain the activity of cyclin
E/CDK2 complexes (Bacqueville et al., 1998; Collado et al., 2000;
Graff et al., 2000; Vervoorts and Luscher, 2008). When FBS was
removed from the incubation medium for 24 h, the cytosolic
p27Kip1 level was high, whereas re-addition of FBS reduced it by
65% within 5min. This effect persisted for 8 h, the longest time-
point measured (Figure 4A). Eight hours after re-addition of FBS,
dnp110αK802R strongly increased the level of p27Kip1 compared
to the EGFP control. In contrast, expression of dnp110βK805R
was ineffective, although dnp110βK805R reduced the phosphory-
lation of P-Akt as effectively as dnp110αK802R (Figure 4B). Only
the p110α inhibitor AS-252424 but not the p110β inhibitor TGX-
221 increased the levels of p27Kip1 (Figures 4C,D), confirming the
results obtained with the dn isoforms.
Inhibition of p27Kip1 synthesis with p27Kip1siRNA indicated
that p27Kip1 was indeed relevant for nuclear BrdU uptake.
Compared to controls, transfection of the cells with non-
silencing RNA neither affected the cytosolic levels of p27Kip1
nor the number of BrdU labeled nuclei (Figure 4E). In contrast,
transfection of the cells with p27Kip1siRNA abolished p27Kip1
and increased by 30% the number of nuclei which had taken
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FIGURE 2 | Inhibition of p110α and p110β reduces the nuclear uptake of
BrdU. (A) Effects of dnp110αK802R (dnp110α) and wtp110α (n = 70);
(B) effects of dnp110βK805R (dnp110β), wtp110β, and dnp110γK833R
(dnp110γ) (n values between 40 and 60); (C) effects of AS-252424 (5μM,
AS), TGX-221 (200 nM, TGX), and wortmannin (100 nM, Wo) (n values of all
groups 30). In all experiments, FBS withdrawal for 24 h was followed by
re-addition of 10% FBS re-addition for 16 h. Transfections of recombinant
p110 isoforms had been performed as described in Materials and Methods.
Pharmacological inhibitors were applied together with FBS. Means ± CI
(0.95) are shown; ∗ ∼ p < 0.05 compared to control.
up BrdU (Figures 4E,F). In such cells, AS-252424 indeed no
longer reduced the nuclear uptake of BrdU. In contrast, TGX-
221 strongly reduced BrdU uptake in cells transfected with
p27Kip1siRNA (Figure 4F), confirming that it did not act via
p27Kip1.
p110β PROMOTES G1/S PHASE TRANSITION BY INACTIVATING GSK-3β
PI3-kinases inactivate GSK-3β by phosphorylating it at Ser9.
Also in neocortical cultures, FBS withdrawal strongly reduced
GSK-3β phosphorylation, whereas re-addition of FBS increased
FIGURE 3 | Short- and long-term effects of 110β inhibition in
neocortical astroglial cells. (A) Transfection with dnp110β (lower panels)
decreases nuclear staining of BrdU (left panels). Cells transfected with
vector coding for EGFP (upper panels) are shown as controls. DAPI staining
shows all nuclei (right panels). (B) TGX-221 (200 nM) decreases the total
cell number, when applied for 3 days. GFAP staining (upper panels); DAPI
staining (lower panels). (B) Quantitation of DAPI staining; means ± CI
(0.95); ∗ ∼ p < 0.05 compared to controls; n ≥ 12; scale bars ∼ 10μm.
it (Figure 5A). Within 1min after re-addition, FBS induced
the phosphorylation of GSK-3β and maintained it during
the next 11 h, the longest time-point measured. The subse-
quent experiment was performed 8 h after re-addition of FBS.
Compared to the respective controls, expression of dnp110αK802R
or dnp110βK805R significantly decreased the phosphorylation of
GSK-3β (Figure 5B). Also pharmacological inhibition of p110α
and p110β with AS-252424 or TGX-221 reduced the phos-
phorylation of GSK-3β by 40% (Figures 5C,D). Their com-
bination reduced the cytosolic levels of P-GSK-3β and P-Akt
like wortmannin. The latter reduced the phosphorylation of
GSK-3β stronger than AS-252424 or TGX-221 given alone
(Figures 5C,D).
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FIGURE 4 | Inhibition of p110α enhances the cellular level of p27Kip1 and
thereby reduces BrdU uptake. (A) Upper lane: p27Kip1 levels in cells
maintained in FBS-free culture medium (-FBS) for 24 h or after re-addition of
10% FBS for 5min up to 8 h. Lower lane: GAPDH served as input control.
(B) Upper lane: levels of p27Kip1 in cells expressing dnp110αK802R (dnp110α)
or p110βK805R (dnp110β). After prior FBS withdrawal for 24 h, 10% FBS had
been added for 8 h. Controls for dnp110α ∼ EGFPα; controls for
dnp110β ∼ EGFPβ;P-Akt levels are shown the middle lane. GSK-3β served as
input control (lower lane). (C) Upper lane: levels of p27Kip1 in cells treated
with AS-252424 (5μM, AS) and/ or TGX-221 (200 nM, TGX). After prior FBS
withdrawal, 10% FBS which contained the drugs had been added for 8 h;
P-Akt levels (middle lane); total Akt served as input control (lower lane).
(D) Quantification of the Western blot experiments. The ratio of the density
of the p27 and total Akt bands was calculated; means of controls were taken
as 100% [means ± CI (0.95) are shown; n = 5; ∗ ∼ p < 0.05 compared to
control]. (E) Upper lane: levels of p27Kip1 protein in cells transfected with
p27Kip1siRNA (p27si) or non-silencing RNA (ns). Cells were transfected for
48 h. During the last 24 h, they were maintained in FBS-free medium. Total
Akt served as input control (lower lane). (F) Effects of AS-252424 (5μM, AS)
and TGX-221 (200 nM, TGX) on nuclear BrdU uptake in cells transfected with
p27Kip1siRNA (p27si); non-silencing RNA (ns). Cells were transfected for 48 h.
During the last 24 h they were FBS-starved. Subsequently, 10% FBS was
re-added for 16 h. The pharmacological inhibitors were present during this
time. The number of BrdU positive nuclei was compared to all nuclei present
as stained with DAPI. Means ± CI (0.95) are shown; n ≥ 30 for all groups,
∗ ∼ p < 0.05 compared to respective controls.
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FIGURE 5 | Inhibition of p110β decreases the phosphorylation of GSK-3β
and thereby reduces BrdU uptake. (A) Upper lane: time-course of GSK-3β
phosphorylation (P-GSK-3β) after FBS removal for 24 + n h (–FBS) as well as
after re-addition of FBS for n h (+FBS). GAPDH served as input control (lower
lane). (B) Upper lane: effects of dnp110αK802R (dnp110α) and
p110βK805R (dnp110β) on the phosphorylation of GSK-3β. After prior FBS
withdrawal, 10% FBS was added for 8 h. Vehicle-treated controls (co);
controls for dnp110αK802R ∼ EGFPα; controls for p110βK805R ∼ EGFPβ
Wortmannin (100 nM, wo) was added together with FBS. Middle lane: P-Akt
in lysates of the same cells. Lower lane: total GSK-3β served as input control.
(C) Upper lane: effects of AS-252424 (5μM, AS) and TGX-221 (200 nM, TGX)
on phosphorylation of GSK-3β. After prior FBS withdrawal, 10% FBS was
added for 8h. Drugs were added together with FBS. (D) Quantification of
Western blot experiments [mean ± CI (0.95) are shown; n = 4; ∗ ∼ p < 0.05
compared to controls]. (E) Upper lane: levels of GSK-3β protein in cells
transfected for 48 h with GSK-3β siRNA (GSKsi) or non-silencing RNA (ns).
GAPDH served as input control. (F) Effects of TGX-221 (200 nM, TGX) and
AS-252424 (5μM, AS) on nuclear uptake of BrdU in cells transfected with
GSK-3β siRNA. For further explanation see Figures 2B,C. Mean ± CI (0.95)
are shown; n ≥ 30; ∗ ∼ p < 0.05 compared to GSKsi group.
Transfecting the cells with GSK-3β siRNA strongly reduced
GSK-3β synthesis as compared to controls or cells transfected
with non-silencing RNA (Figure 5E). In such cells RNA the num-
ber of nuclei labeled with BrdU remained unchanged as compared
to controls (Figure 5F). In cells transfected with GSK-3β siRNA,
however, the p110β inhibitor TGX-221 no longer reduced the
number of BrdU labeled nuclei, whereas the p110α inhibitor AS-
252424 reduced it by approximately 60% (Figure 5F). These data
suggested that only p110β facilitated G1 phase progression by
inhibiting GSK-3β.
p110α AND p110β FACILITATE NUCLEAR BrdU UPTAKE IN THE
MARGINAL ZONE OF RAT NEOCORTEX
Since our initial experiments suggested that PI3-kinases affected
cell cycle progression only in a subgroup of neocortical astroglial
cells, we studied whether these cells had a specific location. In
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organotypic slices prepared from neocortices of newborn rats and
treated with BrdU from DIV 3–7, we analyzed the distribution of
BrdU labeled nuclei. Close to the pial surface, labeled nuclei were
more numerous than in deeper cortical areas (Figure 6A), con-
firming a previous observation by Ichikawa et al. (1983). When
we applied the p110α inhibitor PIK-75 (200 nM) (Knight et al.,
2006) or the p110β inhibitor TGX-221 (200 nM) from DIV 3–7,
the number of BrdU labeled nuclei was reduced by approximately
50% in the area close to the pial surface, which corresponded to
theMZ (Figure 6B). Combined application of both agents did not
produce a stronger effect (Figure 6B). Applied alone or together,
PIK-75 and TGX-221 did not affect the BrdU labeling in more
ventral areas (Figure 6C).
FIGURE 6 | Pharmacological inhibitors of p110α and p110β decrease the
nuclear staining of BrdU in the marginal zone of the neocortex. After
3 days in culture, slice cultures of the neocortex were treated for 4 days
with 200 nM TGX-221 and/or 200 nM PIK-75, an inhibitor of p110α.
(A) Micrographs of slices show BrdU stainings. Solid lines indicate pial
surface; broken lines show the ventral border of marginal zone; calibration
bars ∼ 200μm. (B) Quantitation of BrdU positive cells in the marginal zone.
(C) Quantitation of BrdU positive cells in ventral layers of the neocortex.
Means ± CI (0.95) are shown; n ≥ 17; ∗ ∼ p < 0.05 compared to controls.
(D) Cartoon of the areas prepared shows marginal zone (MZ), deeper layers
of neocortex (Cx), and ventricular zone (VZ). (E) Quantitation of nuclear
staining of BrdU, which was compared to the number of GFAP positive
cells. Means ± CI (0.95) are shown; n ≥ 8; ∗ ∼ p < 0.05 compared to
controls.
To further investigate the area-dependent effects of the p110
inhibitors, we dissected neocortices from 5 days old rats into
the MZ and deeper cortical layers (Cx) as well as the ven-
tricular zone (VZ) (Figure 6D). In the resulting cultures, most
cells were GFAP positive and thus considered to be astrocytes
(data not shown). TGX-221 reduced the nuclear uptake of BrdU
only in astroglial cells prepared from the MZ of the neocortex
(Figure 6E).
DISCUSSION
In cultured neocortical astroglial cells, p110α and p110β medi-
ated nuclear uptake of BrdU via different mechanisms. Whereas
p110α reduced the protein levels of the CDK2-inhibitor p27Kip1,
p110β phosphorylated and inactivated GSK-3β. The PI3-kinases
facilitated S phase entry only in cells dissected from the MZ of the
neocortex.
Neocortical astroglial cells are generated during sequential
stages of development. During embryonic development, radial
glial cells in the VZ are transformed into astroglial cells (Choi
and Lapham, 1978; Schmechel and Rakic, 1979; Kriegstein and
Alvarez-Buylla, 2009). During the early postnatal period, inter-
mediate progenitor cells originating from radial glial and/or
neuroepithelial cells proliferate and produce astroglial cells. The
radial glial cells and progenitors are located in the ventricular
and subventricular zone (Grove et al., 1993; Luskin et al., 1993;
Qian et al., 2000; McCarthy et al., 2001; Kriegstein and Alvarez-
Buylla, 2009). During embryonic development, additional neural
progenitors appear in the preplate and MZ. They continue to
proliferate during the peripartal period and give rise to neurons,
astroglial, and oligodendroglial cells which are mainly located in
the outer Cx (Costa et al., 2007). Thus, astroglial cells from dis-
tinct neocortical areas differ in their origin. The present data
show that PI3-kinases regulate S phase entry in a subgroup of
astroglial cells. Only in cells dissected from the MZ, inhibition
of PI3-kinases reduced by approximately 40% the number of
BrdU labeled nuclei. Combined application of p110α and p110β
inhibitors caused a stronger reduction in nuclear BrdU uptake
than inhibition of a single isoform. Whether both isoforms were
expressed in two distinct cell populations remained unclear. In
most neocortical astroglial cells, S phase entry was indepen-
dent of endogenous PI3-kinases. This finding is in agreement
with data that genetic inactivation of p110β does not induce
striking changes in cortical development (Ciraolo et al., 2008).
In vivo, astroglial cells which enter S phase independently of PI3-
kinases may compensate for the lack of PI3-kinase dependent
cells. After 10 DIV, PI3-kinase inhibition reduced the number
of BrdU labeled nuclei by approximately 50% in our cultures,
suggesting a rapid growth of this subgroup.
Cultured astroglial cells harvested from deep neocortical layers
also showed nuclear BrdU uptake, which was independent of PI3-
kinases. Some of these deep layer cells may have been be silent
astrocytes, which regained the ability to proliferate in response to
the dissociation procedure (Buffo et al., 2008).
According to genetic evidence, p110β may have functions
independent of its kinase activity. Homozygous mice with
deleted p110α or p110β die during early embryonic development
(Bi et al., 1999, 2002). Also knock-in mice expressing kinase-dead
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p110α die at an early embryonic stage (Foukas et al., 2006),
whereas knock-in mice expressing kinase-dead p110β appear to
be normal (Ciraolo et al., 2008). Moreover, deletion of p110β
reduces the proliferation ofmouse embryonic fibroblasts, whereas
proliferation is unaltered in fibroblasts expressing kinase-dead
p110β. Consequently, it has been suggested that non-catalytic
p110β may act as a scaffold for proteins involved in prolifera-
tion (Ciraolo et al., 2008; Jia et al., 2008). In our experiments,
the kinase-dead isoform p110βK805R as well as TGX-221, which
blocks the ATP binding site of p110β (Condliffe et al., 2005;
Knight et al., 2006) reduced nuclear BrdU uptake, indicating that
the kinase domain was involved.
PI3-kinases are known to regulate the cellular levels of
p27Kip1, which inhibits the cyclin E/CDK2 complex (Bacqueville
et al., 1998; Collado et al., 2000; Graff et al., 2000; van Duijn
and Trapman, 2006; Chu et al., 2008; Vervoorts and Luscher,
2008). Dnp110αK802R and the p110α inhibitor AS-252424
enhanced the cellular level of p27Kip1 in our cultures, whereas
dnp110βK805R and the p110β inhibitor TGX-221 were without
effect. This increase in p27Kip1 levels was linked to BrdU labeling.
Transfection of the cells with p27Kip1siRNA reduced the cellular
level of p27Kip1, enhanced the number of BrdU labeled nuclei
and indeed prevented the reducing effect of AS-252424. In con-
trast, in cells treated with p27Kip1siRNA the effect of TGX-221 on
nuclear BrdU labeling remained unchanged. Taken together, these
data strongly suggest that p110α mediates the G1/S phase transi-
tion by lowering p27Kip1 levels. Synthesis and degradation tightly
regulate the cellular levels of p27Kip1. Members of the class O of
forkhead transcription factors (FOXOs) enhance the cellular level
of p27Kip1 (Medema et al., 2000; Stahl et al., 2002). PI3-kinases
phosphorylate FOXOs. They also phosphorylate p27Kip1 and thus
cause its cytosolic accumulation and inactivation (Marques et al.,
2008). Moreover, PI3-kinases can induce the ubiquitination and
proteasomal degradation of p27Kip1 (Nakayama and Nakayama,
2006). Which of these actions was exerted by p110α in our
astroglial cells remained open.
In our cultures, both p110α and p110β phosphorylated GSK-
3β at Ser9 confirming previous data (Cross et al., 1995). However,
in cells treated with GSK-3β siRNA or the antagonist CHIR-
99021 only the p110β antagonist TGX-221 lost its inhibitory
effect on nuclear labeling with BrdU, whereas the p110α inhibitor
AS-252424 remained active. Apparently, only p110β facilitated
nuclear BrdU labeling by inhibiting GSK-3β GSK-3β can reduce
proliferation by initiating the translocation of cyclin D from the
nucleus to the cytosol and thus its ubiquitin-dependent prote-
olysis. This process can be blocked by PI3-kinases (Diehl et al.,
1998). Inhibition of GSK-3β also stabilizes β-catenin in its effect
on proliferation in neuronal progenitors (Mao et al., 2009).
Infection of the cells with an adenoviral vector coding for
wtp110α increased by 120% the number of BrdU labeled nuclei
as compared to controls. In glioblastoma multiforme, loss-of-
function mutations of the phosphatase PTEN which enhance
PI(3,4,5)P3 levels as well as gain of function mutations of p110α
and of the regulatory subunit p85 have been found. Therefore, it
has been suggested that PI3-kinases may be involved in the patho-
genesis of such tumors (Ligresti et al., 2009; Jones and Holland,
2011a,b). In glioma cell lines, inhibition of GSK-3β by LiCl indeed
increases proliferation (Atkins et al., 2012). Whether the tumori-
genic contribution of PI3-kinases depends on the location and
origin of the glial cells, has to be further studied.
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